AAD 2026: Toward Precision Medicine in Psoriasis – What It Means for Patients
In this overview, Lars Werner, CEO of the Danish Psoriasis Association, reflects on the key takeaways from AAD 2026 and shares his perspective on how precision medicine, biomarkers, and new systemic treatments are reshaping psoriasis care and changing the understanding of psoriasis as a complex inflammatory disease.
Relateret indhold
Brænder du for at skrive?
Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk
Send mail til redaktionen